不同剂量瑞舒伐他汀口服对冠心病心力衰竭的应用价值分析

Application Value Analysis of Different Doses of Rosuvastatin Oral Administration for Coronary Heart Failure Patients

目的探析冠心病心力衰竭患者应用瑞舒伐他汀治疗的适当剂量。方法选取2017年4月至2018年3月我院收治的冠心病心力衰竭的患者104例,依入院顺序将患者平均分为低剂量组和高剂量组,分别应用10mg/d和20mg/d的瑞舒伐他汀治疗。观察患者治疗前后的心功能指标、6min步行距离和生活质量。结果两组患者治疗后的LVEF、EDV水平和6min步行距离均明显高于治疗前(P<0.05),ESV水平和MLHFQ评分明显低于治疗前(P<0.05),且高剂量组患者治疗后的LVEF、EDV和6min步行距离更高(P<0.05),ESV水平和MLHFQ评分更低(P<0.05)。结论两种剂量的瑞舒伐他汀均可改善冠心病心力衰竭患者的心功能和生活质量,但高剂量瑞舒伐他汀的效果更佳。

Objective To explore appropriate dosage of rosuvastatin for coronary heart failure patients.Methods Choose 104 cases CHF patients admitted to our hospital from April 2017 to March 2018,divide them into low-dose and high-dose group according to admission sequence,which was reated with 10 mg/d and 20 mg/d rosuvastatin respectively.Observe cardiac function,6-minute walking distance and life quality before and after treatment.Results LVEF,EDV levels and 6-minute walking distance after treatment in both groups were significantly higher than before treatment(P<0.05),ESV level and MLHFQ scores were significantly lower than before treatment(P<0.05).LVEF,EDV levels and 6-minute walking distance in high-dose group were higher after treatment(P<0.05),and ESV level and MLHFQ scores were lower,(P<0.05).Conclusion Both doses of rosuvastatin can improve cardiac function and life quality of coronary heart failure patients,but high doses of rosuvastatin have better effect.